NEXGARD SPECTRA 38 MG 8 MG VETERINARY

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Nopērc to tagad

Lietošanas instrukcija Lietošanas instrukcija (PIL)
24-10-2023
Produkta apraksts Produkta apraksts (SPC)
24-10-2023

Aktīvā sastāvdaļa:

AFOXOLANER; MILBEMYCIN OXIME

Pieejams no:

BEIT-EREZ HAVAT MILATIN LTD

Zāļu forma:

CHEWABLE TABLETS

Kompozīcija:

AFOXOLANER 37.5 MG; MILBEMYCIN OXIME 7.5 MG

Ievadīšanas:

PER OS

Receptes veids:

Not required

Ražojis:

BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Ārstēšanas norādes:

For the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (Dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of Angiostrongylus vasorum) and/or treatment of gastrointestinal nematode infestations is indicated.Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs for 5 weeks.Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) in dogs for 4 weeks.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Ancylostoma braziliense and Ancylostoma ceylanicum) and whipworm (Trichuris vulpis).Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum) with monthly administration.Treatment of demodicosis (caused by Demodex canis).Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

Autorizācija datums:

2022-09-30

Lietošanas instrukcija

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Izlasiet visu dokumentu
                                
                            

Produkta apraksts

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Izlasiet visu dokumentu
                                
                            

Dokumenti citās valodās

Lietošanas instrukcija Lietošanas instrukcija arābu 24-10-2023
Lietošanas instrukcija Lietošanas instrukcija ivrits 24-10-2023

Meklēt brīdinājumus, kas saistīti ar šo produktu